In Vitro Diagnostics Business Outlook: Volume 1, Issue 22 - Glucose Testing
12 Sep 2022
Categories:
In Vitro Diagnostics Business Outlook
A new twice-monthly publication dedicated to IVD, In Vitro Diagnostics Business Outlook offers the following:
• Market Sizing and Forecasting of IVD Market Segments in Every Issue
• Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care–Updates on the Important Test Categories You Need to Know About
• Industry Watch – Developments with COVID-19 and Other Testing
• M&A, Distribution, Partnerships Tracked and Charted
• New Product Introductions and Company Announcements
• Company Profiling and Quarterly Results Summaries
• Regional Market Coverage
Table of Contents
- Untitled Chapter
-
Market Analysis: Glucose Testing
- Overview of Glucose Testing
-
Market Outlook
- Major Product Activity
-
Company Briefs
- Abbott Diagnostics
- Roche
- Dexcom
- Regional Market
-
Executive News Briefing
-
Briefs
- Prolocor Closed $5.2 million in Funding
- Startup Monod Bio Raises $25 Million
- Biotia Raises $8 Million in Series A Funding
- OPKO Health Announces Leadership Change at BioReference Labs
-
Briefs
-
Financial Highlights: Accelerate Diagnostics, Becton Dickinson, OraSure Technologies
-
Accelerate Diagnostics Reports 28% Increase for Half Year 2022
- Becton Dickinson Reports 6% Base Revenue Growth in Third Quarter Fiscal 2022
- OraSure Technologies Reports Q2’22 Record Revenue, +39% Year-Over-Year
-
Accelerate Diagnostics Reports 28% Increase for Half Year 2022
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Mergers and Acquisitions
-
Industry Watch
- COVID-19 Update
-
Region Watch
- Africa
- United States
-
Broad-based Company Announcements
-
Announcements
- Pillar Biosciences Snags NMPA Approval for oncoReveal
- Nanostics Secures CE Mark for ClarityDX Prostate Test
- Aspira Women’s Health Announces Public Offering
-
Announcements
- More Newsletters from Science and Medicine Group